These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9633814)

  • 1. Pooled analysis of p53 mutations in hematological malignancies.
    Prokocimer M; Unger R; Rennert HS; Rotter V; Rennert G
    Hum Mutat; 1998; 12(1):4-18. PubMed ID: 9633814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors.
    Bhatia KG; Gutiérrez MI; Huppi K; Siwarski D; Magrath IT
    Cancer Res; 1992 Aug; 52(15):4273-6. PubMed ID: 1638540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance.
    Peller S; Rotter V
    Hum Mutat; 2003 Mar; 21(3):277-84. PubMed ID: 12619113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
    Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
    Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract.
    Law JC; Whiteside TL; Gollin SM; Weissfeld J; El-Ashmawy L; Srivastava S; Landreneau RJ; Johnson JT; Ferrell RE
    Clin Cancer Res; 1995 Jul; 1(7):763-8. PubMed ID: 9816043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
    Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
    Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The difference between p53 mutation frequency in haematological and non-haematological malignancies: possible explanations.
    Calin G; Ivan M; Stefanescu D
    Med Hypotheses; 1999 Oct; 53(4):326-8. PubMed ID: 10608267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study.
    Casson AG; Evans SC; Gillis A; Porter GA; Veugelers P; Darnton SJ; Guernsey DL; Hainaut P
    J Thorac Cardiovasc Surg; 2003 May; 125(5):1121-31. PubMed ID: 12771886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma.
    Khan SA; Taylor-Robinson SD; Carmichael PL; Habib N; Lemoine NR; Thomas HC
    Int J Oncol; 2006 May; 28(5):1269-77. PubMed ID: 16596244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
    Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
    J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Database and software for the analysis of mutations in the human p53 gene.
    Cariello NF; Cui L; Beroud C; Soussi T
    Cancer Res; 1994 Aug; 54(16):4454-60. PubMed ID: 8044795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
    Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin.
    Luo JL; Tong WM; Yoon JH; Hergenhahn M; Koomagi R; Yang Q; Galendo D; Pfeifer GP; Wang ZQ; Hollstein M
    Cancer Res; 2001 Nov; 61(22):8158-63. PubMed ID: 11719445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations.
    Shahedian B; Shi Y; Zou M; Farid NR
    Mol Genet Metab; 2001 Feb; 72(2):155-63. PubMed ID: 11161841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
    Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
    Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.